Drug Detail

Information about Cixutumumab + Temsirolimus

Generic Name	Cixutumumab + Temsirolimus
IND	IMC-A12 + CCI-779
Brand Name (US)
Manufacturer	ImClone
Drug Type	monoclonal antibody
Delivery	Intravenous
Approval Status	Imc-A12 is in phase 2, CCI-779 is approved for refractory kidney cancer. This combination is in phase 1 & 2 trials for solid tumors and non-GIST cancers.
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor + mTOR Inhibitor

IMC-A12 is an IGF1R inhibitor in early development. IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs.
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.
CCI-779 is an approved mTOR inhibitor. mTOR is a rather general cancer target. There are recent reports (e.g., AACR 2009) that suggest drugs that inhibit IGF-1R and mTOR inhibitors might work well together.